We certainly should in the very short term. Those are the things that are going to make a difference for our patients tomorrow. Many of the other things we've talked about around the table will take some time to roll out. What we have to ensure is that the regulatory process is as facilitative as possible to ensure that molybdenum anywhere along the supply and production chain of radiopharmaceuticals is made as rapidly as possible. As I said, I got my approval for my clinical trial application for fluoride in under a week. It actually came faster than I was able to implement it.
